It is exciting to see that CARB-X today announced that it is seeking to partner with up to 6 additional accelerator organizations to expand its drug development and business support for its growing pipeline of early development antibacterial research projects. The Powered by CARB-X portfolio currently has 22 active projects in its pipeline, with more project announcements said to be imminent.
According to the press release, CARB-X is aiming to partner with additional accelerators in Europe, North America, and the rest of the world to support the Powered by CARB-X portfolio. Up to two accelerators from each of those regions will be selected. The new accelerators will provide a broad range of support to projects funded by CARB-X, address common support needs across projects, and help build the community of people dedicated to fighting drug resistant bacteria.
The new accelerators will be in addition to existing accelerators in the CARB-X network: California Life Sciences Institute (CLSI), RTI International, MassBio, and Wellcome Trust (which is both an accelerator and a funder).
To be considered, accelerator applicants must be a going concern and must be able to work in a fully non-dilutive model. You can find the full Request for Proposals (RFP) here. To apply, click here. And finally, the full press release can be found on line here. Applications are welcome until March 30, 2018.
All best wishes, --jr
John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog-index.html
Upcoming meetings of interest to the AMR community: